Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04180176 · ClinicalTrials.gov registry record · Phase 4
Prospective Clinicogenomic Program
A Phase 4 study of Non-small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC), sponsored by Genentech.
- Completed
- Registry status
- Phase 4
- Development phase
- 945
- Enrollment target
- 20
- Study locations
NCT04180176: Completed Phase 4 study of Non-small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC), sponsored by Genentech.
NCT04180176 is a Phase 4 study of Non-small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) that has completed, run by Genentech. The registered enrollment target is 945 participants, above the 269-participant average among 59 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (251% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04180176, a Phase 4 study of Non-small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC), has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 945 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the feasibility of a scalable, prospective research program for participants with metastatic non-small cell lung cancer (mNSCLC) or extensive-stage small-cell lung cancer (ES-SCLC) planning to start standard-of-care (SOC) systemic anti-cancer treatment. The study will also examine ctDNA status over the course of treatment as a predictor of response to therapy.
Conditions Studied
Interventions
- OTHER Blood Draw
Study Locations (20)
Florida
- Florida Cancer Specialists; Department of Oncology - Fort Myers
- Florida Cancer Specialist, North Region - St. Petersburg
- SCRI Florida Cancer Specialists PAN - Tallahassee
- Florida Cancer Specialists - West Palm Beach
New York
- Hematology Oncology Associates of Central New York - East Syracuse
- West Clinic - New York
- National Translational Research Group - Port Jefferson Station
Alabama
- Alabama Oncology - Birmingham
- Clearview Cancer Institute - Huntsville
Georgia
- University Cancer & Blood Center, LLC; Research - Athens
- Piedmont Cancer Institute, PC - Atlanta
Arizona
- Ironwood Cancer & Research Centers - Chandler
Connecticut
- Yale University - New Haven
Indiana
- Fort Wayne Med Oncology & Hematology Inc - Fort Wayne
Michigan
- Cancer & Hematology Centers of Western Michigan - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 945 participants |
| Start Date | 2019-12-13 |
| Est. Completion | 2023-11-30 |
| Phase | Phase 4 |
What the finished NCT04180176 record still lists
NCT04180176 is an interventional study that assigns participants to a tested intervention. The registered 945 participants enrollment target is mid-sized for trials with a published cap, above the 269-participant average among 59 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (251% higher).
The record links to 2 conditions, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 1 intervention - of which Blood Draw is the first listed.
NCT04180176 names 20 study sites across 13 states, led by Florida, New York, Alabama.
Frequently Asked Questions
What is clinical trial NCT04180176 about?
NCT04180176 is a clinical study titled "Prospective Clinicogenomic Program". The main purpose of this study is to evaluate the feasibility of a scalable, prospective research program for participants with metastatic non-small cell lung cancer (mNSCLC) or extensive-stage small-cell lung cancer (ES-SCLC) planning to start standard-of-care (SOC) systemic anti-cancer treatment. ...
What is the current status of trial NCT04180176?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 945 participants. The study started on 2019-12-13. Estimated completion is 2023-11-30.
What conditions does trial NCT04180176 study?
This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC).
What interventions are being tested in trial NCT04180176?
The interventions under investigation include: Blood Draw (OTHER).
Who is sponsoring clinical trial NCT04180176?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04180176 being conducted?
This trial has 20 study locations across Alabama, Arizona, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-small Cell Lung Cancer (NSCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04180176's enrollment target sits among peer trials
945 3rd of 59 higher than 57 of 59 other Non-small Cell Lung Cancer (NSCLC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-small Cell Lung Cancer (NSCLC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
RECRUITING · Phase 3
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
RECRUITING · Phase 3
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05020236 · 944 participants · Phase 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- NCT06087224 · 947 participants · NA
The TELENEO Trial: A Multicenter Trial of Telemedicine for Advanced Neonatal Resuscitations in Community Hospitals
- NCT06808334 · 942 participants
CLAiR Pivotal Study
- NCT07190209 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI